JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 3 filers reported holding JUNO THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,712,000 | 0.0% | 61,900 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $1,712,000 | +17.1% | 61,900 | +27.9% | 0.01% | +8.3% |
| Q2 2017 | $1,462,000 | +37.5% | 48,400 | 0.0% | 0.01% | +20.0% |
| Q1 2017 | $1,063,000 | -55.2% | 48,400 | -19.3% | 0.01% | -63.0% |
| Q2 2016 | $2,374,000 | +36.2% | 60,000 | +27.1% | 0.03% | +28.6% |
| Q1 2016 | $1,743,000 | -34.0% | 47,200 | -3.1% | 0.02% | -36.4% |
| Q4 2014 | $2,640,000 | – | 48,700 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |